News

Utibron Neohaler (indacaterol/glycopyrrolate), which is expected to be available in the first quarter of next year, can be used for the long-term maintenance treatment of airflow obstruction in

This trial is the first to evaluate the safety and efficacy of OCA in Japanese NASH patients. The primary efficacy analysis was conducted on an intention to treat

The biopharmaceutical firm expects to enroll patients later this year. ProMetic is currently undertaking a phase II clinical trial of PBI-4050 in Canada in patients with metabolic syndrome

The companies will use CEVEC’s CAPGo technology which is optimal for the production of these otherwise difficult to produce recombinant glycoproteins. Financial details of this agreement were not

The NDA is supported by clinical studies exploring the use of 12 weeks of SOF/VEL for patients with genotype 1-6 HCV infection, including patients with compensated cirrhosis and

The Institute of Cancer Research (ICR), London, carried out the study on Olaparib drug with the Royal Marsden NHS Foundation Trust and other funding bodies. The drug was

Yervoy, a monoclonal antibody that blocks CTLA-4 (cytotoxic T-lymphocyte antigen), is used to treat patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of over 1

The recall affects all Auvi-Q products on the US market and includes both the 0.15 mg and 0.3 mg strengths. It includes lots number 2299596 through 3037230 with

UCSF associate professor in the department of surgery Qizhi Tang is undertaking a research on a novel transplantation immunotherapy that is expected to minimize rates of organ rejection